Ellevest Inc’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ellevest Inc’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-27	Closed	-$1K	–	1452
2021 Q4	$1K	Buy	+27	New	+$666	﹤0.01%	1256

Other funds holding CRNX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ellevest Inc's CRNX Position: Q1 2022 in Review

Ellevest Inc sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2022, closing a stake of 27 shares — an estimated $1K sold.

Ellevest Inc first reported a position in CRNX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 116 funds tracked by Wall St. Rank hold CRNX as of Q1 2022.

Ellevest Inc reported no remaining Crinetics Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Ellevest Inc sold 27 Crinetics Pharmaceuticals shares in Q1 2022, an estimated $1K.
Ellevest Inc first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Ellevest Inc's Crinetics Pharmaceuticals position peaked at $1K in Q4 2021.
116 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2022.

Based on Ellevest Inc's 13F filing for Q1 2022, filed 19 Apr 2022.